Ocugen Price Target Maintained With a $6.00/Share by Chardan Capital
Ocugen Is Maintained at Buy by Chardan Capital
Ocugen Analyst Ratings
Maxim Group Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $4
Ocugen's Promising Pipeline and Strategic Advances Support Buy Rating
H.C. Wainwright Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $7
Maxim Group Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $4
H.C. Wainwright Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $7
Ocugen Analyst Ratings
Chardan Capital Maintains Buy on Ocugen, Maintains $6 Price Target
Maxim Group Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $4
H.C. Wainwright Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $7
Ocugen's Promising Pipeline and Valuation Propel Buy Rating
Ocugen Analyst Ratings
Maxim Group Initiates Ocugen(OCGN.US) With Buy Rating, Announces Target Price $4
Ocugen Initiated With a Buy at Maxim
Ocugen (OCGN) Receives a Buy From Noble Financial
Buy Rating on Ocugen: Strong Financials and Promising Clinical Progress
Analysts Offer Insights on Healthcare Companies: Molina Healthcare (MOH) and Ocugen (OCGN)
Noble Financial Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $8